menu
    • menu
    [{"orgOrder":0,"company":"Biorchestra","sponsor":"SK Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antisense Oligonucleotides","moa":"microRNAs","graph1":"Neurology","graph2":"Discovery","graph3":"Biorchestra","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Biorchestra \/ SK Biopharmaceutical","highestDevelopmentStatusID":"2","companyTruncated":"Biorchestra \/ SK Biopharmaceutical"},{"orgOrder":0,"company":"Biorchestra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"BMD-001","moa":"MiR-485-3p","graph1":"Neurology","graph2":"Preclinical","graph3":"Biorchestra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous injection","sponsorNew":"Biorchestra \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorchestra \/ Not Applicable"},{"orgOrder":0,"company":"Biorchestra","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"BMD-001","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Biorchestra","amount2":0.85999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.85999999999999999,"dosageForm":"","sponsorNew":"Biorchestra \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Biorchestra \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Biorchestra

    Menu

    Biorchestra

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biorchestra

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Biorchestra

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMD-001

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $861.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for ...

                            Details : Under the agreement, Global Biopharmaceutical will Leverage Biorchestra Targeting Technology Platform, BDDS™ to Develop Nucleic Acid Therapies, including BMD-001, for Treatment of Neurological Disorders in Multiple Targets.

                            Brand Name : BMD-001

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 27, 2023

                            Lead Product(s) : BMD-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $861.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biorchestra

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Biorchestra

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BMD-001

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            BIORCHESTRA, Presenting Lead Candidate BMD-001 for Alzheimer's disease and Drug Delivery System Technology at ...

                            Details : BMD-001 (or BDDS : miR-485-3p ASO) is an antisense oligonucleotides encapsulated with proprietary Brin polymer to cross blood-brain barrier and plasma membrane of microglia, astrocyte and neuron to degrade the microRNA 485-3p and treat neuroinflammation ...

                            Brand Name : BMD-001

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 09, 2022

                            Lead Product(s) : BMD-001

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biorchestra

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed

                            Biorchestra

                            South Korea arrow
                            Pharmtech & Ingredients
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SK Biopharmaceuticals, BIORCHESTRA Collaborate to Develop miRNA-Targeted Therapeutics

                            Details : Under the collaboration agreement, BIORCHESTRA, that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology by using antisense oligonucleotides.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 05, 2022

                            Lead Product(s) : Antisense Oligonucleotides

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Sponsor : SK Biopharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth